National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anti-CD30 monoclonal antibody XmAb2513
A humanized monoclonal antibody directed against the cell surface receptor CD30 with potential immunotherapeutic activity. Anti-CD30 monoclonal antibody XmAb2513 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on activated lymphocytes transiently and is constitutively expressed in hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:XmAb2513



Previous:anti-CD20 monoclonal antibody R7159, anti-CD200 monoclonal antibody ALXN6000, anti-CD22 immunotoxin CAT-8015, anti-CD3 immunotoxin A-dmDT390-bisFv(UCHT1), anti-CD30 monoclonal antibody MDX-1401
Next:anti-CD33 monoclonal antibody-DM4 conjugate AVE9633, anti-CD37 single-chain polypeptide TRU-016, anti-CD38 monoclonal antibody, anti-CD45 monoclonal antibody, anti-CD45 monoclonal antibody AHN-12

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov